Santa Rosa, Calif.- A new phase II study published in today’s edition of the Nature Publishing Group’s Prostate Cancer and Prostatic Diseases Journal (www.nature.com/pcan) validates that men diagnosed with recurring prostate cancer in which conventional therapies have failed, may benefit from modified citrus pectin (MCP), a nutrient derived from citrus fruits.
The study tested 10 men on the rate of their prostate-specific antigen doubling time (PSADT) before and after taking PectaSol® MCP (Guess, B.W., Strum, S. et al. 2003. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer and Prostatic Diseases Journal. 6(4): 301-304.). The patients, ages 57 to 79, had undergone prior conventional medical treatments including radical prostatectomy, external beam radiation, or cryosurgery and experienced a recurrence of cancer as determined by rising PSA levels. In this 12-month study, 70 percent (seven) of the patients experienced a significant lengthening in their PSADT, which correlates to slower cancer progression and can lead to prolonged life.
“It is hoped that by slowing the PSADT with MCP we can delay the need for more aggressive therapy and perhaps enhance the quality of life of those patients exhibiting PSA recurrence after surgery or radiation therapy,” says Stephen B. Strum, MD, FACP, a co-author of the study.
Modified citrus pectin is derived from the peels and pulps of fruits, such as oranges and grapefruits, which contain citrus pectin, a naturally occurring soluble fiber. Citrus pectin is processed or “modified” into shorter chain molecules that are more easily absorbed from the digestive tract and into the bloodstream. This modified citrus pectin, once in the bloodstream, becomes a powerful cancer-fighting nutrient, binding to cancer cells and preventing growth and metastasis.
MCP is considered to be one of the top “Super-Eight Natural Medicines for Cancer Treatment” in a book endorsed by the Cancer Treatment Centers of America (Murray, Michael,; Birdsall, Tim,; Pizzorno, Joseph,; and Reilly, Paul, How To Prevent and Treat Cancer with Natural Medicine, New York: Riverhead Books, 2002.). MCP was selected by the authors’ based on five specific criteria: clinical evidence of effectiveness, scientific rationale, safety, compatibility with conventional therapies and the authors’ clinical experience.
MCP binds to galectin-3 molecules, which are over-expressed in certain types of cancer. In a separate published clinical study, MCP has been shown to reduce metastasis in a wide range of other cancers, including breast, colon and lung cancer. MCP has also been shown in a published study to remove heavy metals and carcinogens such as mercury, lead and cadmium from the body, which may contribute to its anti-cancer properties.
“While MCP shows promise to treat a wide range of cancers, this study focused on prostate cancer, since disease progression is easily measured through PSA levels,” says Isaac Eliaz, M.D., L.Ac., a nationally respected cancer expert, clinical practitioner and formulator of Pecta-Sol® MCP, which was used in the study. “This phase two study with MCP has clearly shown effectiveness. Now it’s time to expand the patient pool and move on to phase three research, which we hope to start when funding is available.”
Prostate cancer is the most common type of cancer found in men, second only to skin cancer. Each year more than 220,000 men are diagnosed with prostate cancer including Rudy Giuliani and more recently Robert De Niro. More than 30,000 men died of prostate cancer last year compared to approximately 40,000 deaths of women due to breast cancer.